Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion.
New FP
hepatic arterial infusion chemotherapy
hepatocellular carcinoma
low dose FP
macrovascular invasion
vascular invasion
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Sep 2021
03 Sep 2021
Historique:
received:
15
07
2021
revised:
30
08
2021
accepted:
01
09
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Macroscopic vascular invasion (MVI) is a poor prognostic factor in hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) is a promising treatment in MVI-HCC. However, it is not clear which regimens are suitable for HAIC. In this study, we aimed to compare the therapeutic effects between New FP (a fine-powder cisplatin suspended with lipiodol plus 5-fluorouracil) and low dose FP (LFP/cisplatin plus 5-fluorouracil) in the treatment of MVI-HCC patients with Child-Pugh class A. New FP is a regimen that consists of a fine-powder cisplatin suspended with lipiodol and 5-fluorouracil. Fifty-one patients were treated with LFP, and 99 patients were New FP. We compared the therapeutic effects of LFP and New FP and assessed factors that associated with the therapeutic effects. The median survival and progression-free survival times of LFP and New FP were 16.1/24.7 and 5.4/8.8 months, respectively (
Identifiants
pubmed: 34503259
pii: cancers13174450
doi: 10.3390/cancers13174450
pmc: PMC8431395
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
Liver Cancer. 2015 Sep;4(3):188-99
pubmed: 26674592
Cardiovasc Intervent Radiol. 2021 May;44(5):766-773
pubmed: 33415417
J Gastroenterol. 2012 Jun;47(6):686-95
pubmed: 22382631
Oncology. 2019;96(4):192-199
pubmed: 30650415
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432
pubmed: 29631810
Clin Transl Oncol. 2015 Dec;17(12):988-95
pubmed: 26607931
Jpn J Radiol. 2012 Jan;30(1):10-7
pubmed: 22135111
Oncology. 2010 Jul;78 Suppl 1:148-53
pubmed: 20616598
Ann Oncol. 2016 Nov;27(11):2090-2096
pubmed: 27573564
Liver Cancer. 2019 Nov;8(6):505-519
pubmed: 31799207
Dig Dis. 2011;29(3):339-64
pubmed: 21829027
J Cancer Res Clin Oncol. 2011 Apr;137(4):659-67
pubmed: 20552225
Aliment Pharmacol Ther. 2010 Aug;32(4):543-50
pubmed: 20500734
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Cancer. 2006 May 1;106(9):1990-7
pubmed: 16565970
Surg Today. 2017 Jul;47(7):851-858
pubmed: 28188368
Liver Cancer. 2014 Oct;3(3-4):458-68
pubmed: 26280007
Radiology. 1987 May;163(2):345-51
pubmed: 3031724
J Gastroenterol. 2005 Jan;40(1):70-8
pubmed: 15692792
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Hepatol Res. 2012 May;42(5):442-53
pubmed: 22176468
Mol Clin Oncol. 2017 Dec;7(6):1013-1020
pubmed: 29285366
Liver Cancer. 2017 Nov;6(4):360-374
pubmed: 29234639
Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50
pubmed: 26754678
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Cancer Chemother Pharmacol. 2013 Aug;72(2):463-70
pubmed: 23812005
Hepatol Res. 2012 Jun;42(6):523-42
pubmed: 22568457
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
JAMA Oncol. 2019 Jul 1;5(7):953-960
pubmed: 31070690
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562793
Hepatol Res. 2018 Dec;48(13):1118-1130
pubmed: 30030881
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 2002 Aug 1;95(3):588-95
pubmed: 12209752
J Hepatol. 2017 Jun;66(6):1166-1172
pubmed: 28131794
Gan To Kagaku Ryoho. 1991 Mar;18(3):403-9
pubmed: 2003740